Physician profile
Robert Rush Brown
NPI 1316960040
$1,396.98
in general payments reported to CMS, 2019-2025
22 companies · $20.50 in 2025
The $20.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $152 · 2021: $262 · 2022: $48.41 · 2025: $20.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $187.74 | 2019-2020 | |
| Pfizer INC. | $185.24 | 2019-2025 | |
| Amgen INC. | $165.17 | 2019-2020 | |
| Novo Nordisk INC | $103.13 | 2019-2022 | |
| Astellas Pharma US INC | $88.03 | 2019 | |
| Acclarent, INC | $83.44 | 2021 | |
| Amarin Pharma, INC. | $74.07 | 2020-2021 | |
| Abbvie INC. | $73.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $68.27 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $54.43 | 2019-2020 | |
| Allergan, INC. | $52.74 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $37.18 | 2020-2021 | |
| Boston Scientific Corporation | $32.16 | 2021-2022 | |
| Shire North American Group INC | $31.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.27 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.42 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $22.42 | 2019 | |
| Neos Therapeutics, Lp | $20.18 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.65 | 2019 | |
| Horizon Therapeutics Plc | $14.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.